Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willett, C. G.
Right arrow Articles by Czito, B. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Willett, C. G.
Right arrow Articles by Czito, B. G.

Combined-modality Therapy for Esophageal Cancer

Christopher G. Willett, MD, and Brian G. Czito, MD

From the Department of Radiation Oncology, Duke University Medical Center, Durham, NC

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests Christopher G. Willett, MD, Chair, Department of Radiation Oncology, Duke University Medical Center, Erwin Road, Durham, NC 27710; e-mail: christopher.willett{at}duke.edu

Overview: Esophageal carcinoma is an uncommon cancer, accounting for approximately 1% of all malignancies and 6% of all gastrointestinal malignancies. Although significant advances have been made in the staging and clinical treatment of patients with esophageal cancer, the outcome for these patients remains bleak. Five-year survival rates for esophageal cancer are approximately 11%, with a median survival rate of 9 months. This review highlights contemporary and future treatment strategies in patients with localized esophageal cancer.